Costs and consequences of using interferon-γ release assays for the diagnosis of active tuberculosis in India

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Little, Kristen M ^a   Pai, Madhukar ^b   Dowdy, David W ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; INDIA; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; TREATMENT OUTCOME; XPERT MTB/RIF; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; MICROBIOLOGY; SPUTUM; TUBERCULOSIS;

COST-BENEFIT ANALYSIS; HUMANS; INDIA; INTERFERON-GAMMA RELEASE TESTS; MODELS, ECONOMIC; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS;

EID: 84928710313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124525     Document Type: Article

References (53)

1. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008; 149: 177-184. PMID: 18593687
2. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 45-55. doi: 10.1016/S1473-3099(11)70210-9 PMID: 21846592
3. World Health Organization. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries [Internet]. Geneva, Switzerland: WHO; 2011 pp. 1-75. Available: http://whqlibdoc.who.int/publications/2011/9789241502672-eng.pdf
4. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011; 204 Suppl 4: S1120-1129. doi: 10.1093/infdis/jir410 PMID: 21996694
5. Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2005; 9: 1072-1082.
6. Joshi R, Narang U, Zwerling A, Jain D, Jain V, Kalantri S, et al. Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. Eur Respir J. 2011; 38: 1475-1477. doi: 10.1183/09031936.00014611 PMID: 22130764
7. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA. 2005; 293: 2746-2755. doi: 10.1001/jama.293.22.2746 PMID: 15941804
8. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis. 2001; 183: 469-477. doi: 10.1086/318081 PMID: 11133379
9. Treatment Action Group and Global TB Community Advisory Board. Open Letter to Peter M. Schatz, CEO QIAGEN: Marketing and Use of QuantiFERON-TB Gold for active TB in India and high TB burden countries [Internet]. 2013. Available: http://www.tbonline.info/media/uploads/documents/qiagen-open-letter-final.pdf
10. Qiagen. Qiagen's response to the open letter sent by TAG, TB CAB, and India CAB re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries [Internet]. 2013. Available: http://www.tbonline.info/media/uploads/documents/letter-to-tag18may2013.pdf
11. Qian F, Wang W, Qiu Z, Shen Y, He J, Li D, et al. Evaluation of a new tuberculosis-related interferon gamma release assay for tuberculosis infection diagnosis in Huzhou, eastern China. Indian J Pathol Microbiol. 2013; 56: 125-128. doi: 10.4103/0377-4929.118694 PMID: 24056648
12. Zhang S, Shao L, Mo L, Chen J, Wang F, Meng C, et al. Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clin Vaccine Immunol CVI. 2010; 17: 1985-1990. doi: 10.1128/CVI.00294-10 PMID: 20943878
13. World Health Organization Country Office for India. Standards for TB Care in India [Internet]. India: World Health Organization; 2014. Available: http://www.tbcindia.nic.in/pdfs/STCI%20Book-Final%20%20060514.pdf
14. Rabita A. TB Advocates urge action over misleading blood tests. In: Science Speaks.
15. Menon S, Vachali M, Chitalia M, Pai M. TB Diagnostics in India: Market Analysis and Potential [Internet]. Presentation presented at; 2012 Jul 16; Montreal, Canada. Available: http://tbevidence.org/wpcontent/uploads/2012/07/TB-Diagnostics-Market-Analysis-July16-2012-FINAL.pdf
16. Clinton Health Access Initiative, Social and Rural Research Institute, IMRB International. TB Diagnostics in India's Private Sector. India; 2014 pp. 1-98.
17. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med. 2011; 8: e1001074. doi: 10.1371/journal.pmed.1001074 PMID: 21857810
18. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; 1: CD009593. doi: 10.1002/14651858.CD009593.pub3 PMID: 24448973
19. Stall N, Rubin T, Michael JS, Mathai D, Abraham OC, Mathews P, et al. Does solid culture for tuberculosis influence clinical decision making in India? Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2011; 15: 641-646. doi: 10.5588/ijtld.10.0195
20. World Health Organization. Country TB Reports: India [Internet]. Geneva, Switzerland: World Health Organization; 2012. Available: https://extranet.who.int/sree/Reports?op=Replet&name=/WHO-HQ-Reports/G2/PROD/EXT/TBCountryProfile&ISO2=IN&outtype = pdf
21. Revised National Tuberculosis Control Programme. DOTS-Plus Guidelines [Internet]. New Delhi, India: Central TB Division, Directorate General of Health Services (India); 2010 Jan pp. 1-122. Available: http://health.bih.nic.in/Docs/Guidelines/Guidelines-DOTS-Plus.pdf
22. MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2013; 92: 126-138. doi: 10.2471/BLT.13.124800 PMID: 24623906
23. Raizada N, Sachdeva KS, Sreenivas A, Vadera B, Gupta RS, Parmar M, et al. Feasibility of Decentralised Deployment of Xpert MTB/RIF Test at Lower Level of Health System in India. PLoS ONE. 2014; 9: e89301. doi: 10.1371/journal.pone.0089301 PMID: 24586675
24. World Bank. Inflation, GDP deflator (annual %) [Internet]. Washington, DC: World Bank; 2013. Available: http://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG
25. Historical Exchange Rates. In: OANDA [Internet]. Available: http://www.oanda.com/currency/historicalrates/. Accessed 2014 Sep 15.
26. Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J. 2014; 43: 1793-1796. doi: 10.1183/09031936.00217313 PMID: 24525440
27. Quest4Health | Maintain your health [Internet]. Available: https://www.quest4health.com/cart/view. Accessed 2015 Jan 5.
28. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLoS Med. 2012; 9: e1001347. doi: 10.1371/journal.pmed.1001347 PMID: 23185139
29. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. PLoS Med. 2011; 8: e1001120. doi: 10.1371/journal.pmed.1001120 PMID: 22087078
30. Babu K, Philips M, Subbakrishna DK. Perspectives of Quantiferon TB Gold test among Indian practitioners: a survey. J Ophthalmic Inflamm Infect. 2013; 3: 9. doi: 10.1186/1869-5760-3-9 PMID: 23514565
31. World Health Organization. WHO | Global tuberculosis control - epidemiology, strategy, financing. In: WHO [Internet]. Available: http://www.who.int/tb/publications/global-report/2009/en/. Accessed 2014 Sep 12.
32. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: WHO; 2015 pp. 1-38.
33. Jarosławski S, Pai M. Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Glob Health. 2012; 2: 39-50. doi: 10.1016/j.jegh.2011.12.001 PMID: 23856397
34. Wells W, Ge C, Patel N, Oh T, Gardiner E, Kimerling M. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One. 2011; 6: e18964. doi: 10.1371/journal.pone.0018964 PMID: 21573227
35. Salje H, Andrews JR, Deo S, Satyanarayana S, Sun AY, Pai M, et al. The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. PLoS Med. 2014; 11: e1001674. doi: 10.1371/journal.pmed.1001674 PMID: 25025235
36. Kay M. Private firms form initiative to offer accurate and affordable TB tests. BMJ. 2013; 346: f2161. doi: 10.1136/bmj.f2161 PMID: 23564925
37. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163: 1009-1021. doi: 10.1001/archinte.163.9.1009 PMID: 12742798
38. K. Styblo. Epidemiology of Tuberculosis. Hague R Neth Tuberc Assoc KNCV. 1991;
39. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999; 353: 444-449. PMID: 9989714
40. Foundation for Innovative New Diagnostics., Special Programme for Research and Training in Tropical DiseasesWorld Health Organization. Diagnostics for tuberculosis: Global demand and market potential. Geneva, Switzerland: WHO on behalf of the Special Programme for Research and Training in Tropical Diseases; 2006.
41. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006; 6: 570-581. doi: 10.1016/S1473-3099(06)70578-3 PMID: 16931408
42. Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006; 444 Suppl 1: 49-57. doi: 10.1038/nature05446 PMID: 17159894
43. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: A systematic review. Lancet Infect Dis. 2006; 6: 664-674. PMID: 17008175
44. Pronyk RM, Makhubele MB, Hargreaves JR, Tollman SM, Hausler HP. Assessing health seeking behaviour among tuberculosis patients in rural South Africa. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2001; 5: 619-627.
45. Salaniponi F, Harries AD, Banda H, Kang'ombe C, Mphasa N, Mwale A. Care-seeking behavior and diagnostic processes in patients with smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis. 2000; 4: 327-332. PMID: 10777081
46. Squire SB, Belaye AK, Kashoti A, Salaniponi FML, Mundy CJF, Theobald S, et al. "Lost" smear-positive pulmonary tuberculosis cases: where are they and why did we lose them? Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2005; 9: 25-31.
47. Creek TL, Lockman S, Kenyon TA, Makhoa M, Chimidza N, Moeti T, et al. Completeness and timeliness of treatment initiation after laboratory diagnosis of tuberculosis in Gaborone, Botswana. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2000; 4: 956-961.
48. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global Epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
49. Lu C, et al. A Systematic Review of Reported Cost for Smear and Culture Tests during Multidrug-Resistant Tuberculosis Treatment. PLoS One. 2013; 8: e56074. doi: 10.1371/journal.pone.0056074 PMID: 23457502
50. Prasad R. WHO-approved TB test, now at a subsidised price. The Hindi. Chennai, India; 23 Mar 2013. Available: http://www.thehindu.com/sci-tech/health/whoapproved-tb-test-now-at-a-subsidised-price/article4554843.ece
51. Murray C, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, Massachusetts: Harvard School of Public Health; 1996.
52. Ministry of Health and Family Welfare. RNTCP Status Report. New Delhi, India: Central TB Division, Directorate General of Health Services (India); 2010.
53. Institute of Actuaries of India. Published Mortality Tables. New Delhi, India: Institute of Actuaries of India; 2010.